001     888811
005     20210116101319.0
024 7 _ |a 10.3389/fmicb.2020.01655
|2 doi
024 7 _ |a 2128/26542
|2 Handle
024 7 _ |a altmetric:86608661
|2 altmetric
024 7 _ |a 32849341
|2 pmid
024 7 _ |a WOS:000560547000001
|2 WOS
037 _ _ |a FZJ-2020-05225
082 _ _ |a 570
100 1 _ |a Lee, Jungho
|0 P:(DE-Juel1)168345
|b 0
245 _ _ |a Ustilago maydis Serves as a Novel Production Host for the Synthesis of Plant and Fungal Sesquiterpenoids
260 _ _ |a Lausanne
|c 2020
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1610714533_23281
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Sesquiterpenoids are important secondary metabolites with various pharma- and nutraceutical properties. In particular, higher basidiomycetes possess a versatile biosynthetic repertoire for these bioactive compounds. To date, only a few microbial production systems for fungal sesquiterpenoids have been established. Here, we introduce Ustilago maydis as a novel production host. This model fungus is a close relative of higher basidiomycetes. It offers the advantage of metabolic compatibility and potential tolerance for substances toxic to other microorganisms. We successfully implemented a heterologous pathway to produce the carotenoid lycopene that served as a straightforward read-out for precursor pathway engineering. Overexpressing genes encoding enzymes of the mevalonate pathway resulted in increased lycopene levels. Verifying the subcellular localization of the relevant enzymes revealed that initial metabolic reactions might take place in peroxisomes: despite the absence of a canonical peroxisomal targeting sequence, acetyl-CoA C-acetyltransferase Aat1 localized to peroxisomes. By expressing the plant (+)-valencene synthase CnVS and the basidiomycete sesquiterpenoid synthase Cop6, we succeeded in producing (+)-valencene and α-cuprenene, respectively. Importantly, the fungal compound yielded about tenfold higher titers in comparison to the plant substance. This proof of principle demonstrates that U. maydis can serve as promising novel chassis for the production of terpenoids.
536 _ _ |a 583 - Innovative Synergisms (POF3-583)
|0 G:(DE-HGF)POF3-583
|c POF3-583
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Hilgers, Fabienne
|0 P:(DE-Juel1)167181
|b 1
700 1 _ |a Loeschke, Anita
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Jaeger, Karl-Erich
|0 P:(DE-Juel1)131457
|b 3
700 1 _ |a Feldbrügge, Michael
|0 P:(DE-HGF)0
|b 4
|e Corresponding author
773 _ _ |a 10.3389/fmicb.2020.01655
|g Vol. 11, p. 1655
|0 PERI:(DE-600)2587354-4
|p 1655
|t Frontiers in microbiology
|v 11
|y 2020
|x 1664-302X
856 4 _ |u https://juser.fz-juelich.de/record/888811/files/fmicb-11-01655.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:888811
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)167181
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131457
913 1 _ |a DE-HGF
|b Key Technologies
|l Key Technologies for the Bioeconomy
|1 G:(DE-HGF)POF3-580
|0 G:(DE-HGF)POF3-583
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-500
|4 G:(DE-HGF)POF
|v Innovative Synergisms
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-08-32
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT MICROBIOL : 2018
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-08-32
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-32
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-32
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-08-32
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-08-32
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-32
920 1 _ |0 I:(DE-Juel1)IMET-20090612
|k IMET
|l Institut für Molekulare Enzymtechnologie (HHUD)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IMET-20090612
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21